The future of tobacco
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7522.972 (Published 20 October 2005) Cite this as: BMJ 2005;331:972- Nigel Gray, scientist (nigel@uicc.org)
- International Agency for Research on Cancer, Lyon, France
Tobacco is a perpetually controversial topic. It causes millions of deaths every year and will continue to do so as addiction to nicotine spreads in developing countries in the most popular form of its delivery, the cigarette.
The history of the public health war against tobacco is filled with victories and losses. Many of the victories, such as advertising bans, have been pyrrhic, in that restrictions that fall short of full eradication have been circumvented, and successful marketing has continued through means that are uncontrolled by national parliaments—Formula One motor racing is a good example. Attempts to regulate tobacco as a drug have failed in the United States and have not been seriously attempted elsewhere, although the European Union has some limited restrictions on tar, nicotine, and carbon monoxide. Canada requires disclosure of the constituents of smoke but applies no restrictive regulations.
The decline in the prevalence of smoking is depressingly slow. The smokable forms of the drug are still used by between a quarter and a half of adults in most countries, and use is increasing among women. Although …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.